Search Results

The Atellica IM High-Sensitivity Troponin I (TnIH) assay is for in the quantitative measurement of cardiac troponin I in human serum or plasma (lithium heparin) using the Atellica IM Analyzer. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).

The Atellica IM TnIH assay components include the Atellica IM TnIH Primary Reagent ReadyPack (containing Lite Reagent and Solid Phase Reagent) and the Atellica IM TnIH Calibrator (containing High Calibrator (Cal H) and Low Calibrator (Cal L)). The Lite Reagent contains Bovine serum albumin (BSA) conjugated to a recombinant monoclonal (sheep) Fab anti-human cTnl labeled with acridinium ester in HEPES buffer; stabilizers; preservatives. The Solid Phase Reagent contains Streptavidin-coated magnetic latex particles with 2 biotinylated (mouse and sheep) monoclonal anti-troponin I antibodies in buffer; stabilizers; preservatives. The High Calibrator contains Human serum; human cTnl; preservatives. The Low Calibrator contains HEPES buffer; bovine serum albumin (BSA); surfactants; preservatives. The methodology is Chemiluminescence and the assay protocol is a Sandwich immunoassay.

Here's an analysis of the provided text, focusing on acceptance criteria and study details:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state formal acceptance criteria in a structured table. However, implied acceptance criteria are based on CLSI (Clinical and Laboratory Standards Institute) guidelines and the reported performance of the device. The "High-Sensitivity Designation" section (10.10) presents criteria for classification as a high-sensitivity troponin test.

2. Sample Size Used for the Test Set and Data Provenance

The main test set can be considered the clinical performance study.

• Sample Size: The number of patients varies depending on the timepoint and matrix. For example, for Lithium Heparin Plasma at 0-1.5hr, N=45 for AMI cases and N=401 for non-AMI cases (female/male specific 99th percentiles). When considering overall 99th percentile for both genders, the sample sizes are much larger (e.g., Li Hep Plasma 0-1.5hr, N=145 AMI, N=964 non-AMI).
• Data Provenance:
  • Country of Origin: Specimens were collected at 29 sites from different regions across the United States.
  • Retrospective or Prospective: The study enrolled patients who presented to the emergency department, or ambulatory care center equivalent, with signs or symptoms suspicious for a possible acute coronary syndrome (ACS) event. This indicates a prospective data collection.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

• Number of Experts: An "independent adjudication committee" was used. The exact number of individuals on this committee is not specified, but it's referred to in the plural ("cardiologists").
• Qualifications of Experts: The ground truth for AMI diagnosis was established by cardiologists. No specific years of experience are provided, but their specialty (cardiologist) is a key qualification.

4. Adjudication Method for the Test Set

The adjudication method was performed by an independent committee of cardiologists, based on the Third universal definition of myocardial infarction consensus guideline endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF). The specific methods of consensus (e.g., 2+1, majority vote) within this committee are not detailed in the summary.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

• No MRMC study was done. This device is an in vitro diagnostic (IVD) assay for quantitative measurement of a biomarker (cardiac troponin I), not an AI-based image analysis or decision support system for human readers. Therefore, the concept of human readers improving with or without AI assistance does not apply to this type of device.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

• Yes, a standalone study was done. The performance characteristics (precision, linearity, detection limits, interference, cross-reactivity) and the clinical performance (sensitivity, specificity, PPV, NPV) are all measures of the device's performance as an assay system (Atellica IM TnIH assay on the Atellica IM Analyzer) producing quantitative results. This is inherently a standalone performance evaluation by the device itself, without a human interpretation loop required for the direct output (the quantitative troponin I value). Human clinicians then use this value in conjunction with other clinical findings to make a diagnosis.

7. The Type of Ground Truth Used (Expert Consensus, Pathology, Outcomes Data, etc.)

• The ground truth for the clinical performance study was the adjudicated diagnosis of Acute Myocardial Infarction (AMI). This adjudication was performed by an independent committee of cardiologists based on the "Third universal definition of myocardial infarction consensus guideline." This is a form of expert consensus based on established clinical guidelines and outcomes data.

8. The Sample Size for the Training Set

• The document does not provide information on a training set sample size. This is expected as the Atellica IM TnIH is a traditional IVD assay (immunoassay), not an AI/ML device that requires a separate training phase. The development of such assays involves method development, optimization, and internal validation, but not "training sets" in the context of machine learning.

9. How the Ground Truth for the Training Set Was Established

• As there is no mention of a "training set" in the context of an AI/ML algorithm, this question is not applicable to this device. The assay development would typically involve purified analytes, known concentrations, and reference methods used for calibration and validation during the research and development phase to ensure accurate measurement of cardiac troponin I. The "traceability and value assignment" (Section 10.14) mentions standardization to an internal standard manufactured using human heart homogenate.

Ask a specific question about this device